Tech Company Financing Transactions
Odyssey Therapeutics Funding Round
General Catalyst Partners, Alexandria Venture Investments and Catalio Capital Management participated in a $168 million Series B funding round for Odyssey Therapeutics. The round was announced on 10/13/2022.
Transaction Overview
Company Name
Announced On
10/13/2022
Transaction Type
Venture Equity
Amount
$168,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to advance its portfolio of precision immunomodulators and oncology medicines in support of its mission of developing innovative medicines to treat serious human diseases.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Cambridge office: 301 Binney St
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Website
Email Address
Overview
Odyssey is pioneering next generation precision immunomodulators and oncology medicines for patients through our industry leading discovery engine. We have ambitious goals, and we aim to reach them by breaking down barriers and challenging the status quo.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Gary Glick
Co-Founder
Felix Meissner
Co-Founder
David Pompliano
Browse more venture capital transactions:
Prev: 10/13/2022: Carmine Therapeutics venture capital transaction
Next: 10/13/2022: Fabric Systems venture capital transaction
Share this article
News on VC Transactions
Our team works diligently to document funding rounds that are announced publicly. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs